Police & Firemen s Retirement System of New Jersey Raises Position in Gilead Sciences, Inc. $GILD

Police & Firemen s Retirement System of New Jersey lifted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 4.0% during the second quarter, according to its most recent disclosure with the SEC. The fund owned 189,082 shares of the biopharmaceutical company’s stock after acquiring an additional 7,288 shares during the period. Police & Firemen s Retirement System of New Jersey’s holdings in Gilead Sciences were worth $20,964,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently modified their holdings of GILD. One Wealth Advisors LLC lifted its position in Gilead Sciences by 34.8% during the 2nd quarter. One Wealth Advisors LLC now owns 9,163 shares of the biopharmaceutical company’s stock worth $1,016,000 after acquiring an additional 2,364 shares during the period. Ariel Investments LLC increased its holdings in Gilead Sciences by 7.7% in the 1st quarter. Ariel Investments LLC now owns 430,424 shares of the biopharmaceutical company’s stock worth $48,229,000 after buying an additional 30,630 shares during the period. Wealth Management Associates Inc. purchased a new position in Gilead Sciences during the 2nd quarter worth approximately $255,000. Sivik Global Healthcare LLC lifted its stake in Gilead Sciences by 25.0% during the 2nd quarter. Sivik Global Healthcare LLC now owns 50,000 shares of the biopharmaceutical company’s stock valued at $5,544,000 after acquiring an additional 10,000 shares during the period. Finally, Hussman Strategic Advisors Inc. acquired a new stake in Gilead Sciences during the 2nd quarter valued at approximately $2,328,000. 83.67% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

GILD has been the topic of several analyst reports. Royal Bank Of Canada increased their price target on Gilead Sciences from $100.00 to $105.00 and gave the stock a “sector perform” rating in a research report on Friday, October 31st. BMO Capital Markets upped their target price on Gilead Sciences from $130.00 to $135.00 and gave the stock an “outperform” rating in a research note on Monday, October 20th. Wells Fargo & Company lifted their price target on Gilead Sciences from $140.00 to $145.00 and gave the company an “overweight” rating in a research report on Friday, October 31st. Sanford C. Bernstein restated an “outperform” rating on shares of Gilead Sciences in a research report on Monday, November 3rd. Finally, Citigroup lifted their target price on shares of Gilead Sciences from $125.00 to $135.00 and gave the company a “buy” rating in a report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, Gilead Sciences currently has an average rating of “Moderate Buy” and a consensus target price of $128.78.

Gilead Sciences Stock Performance

GILD opened at $123.40 on Thursday. The firm’s fifty day simple moving average is $116.99 and its two-hundred day simple moving average is $112.55. Gilead Sciences, Inc. has a 52-week low of $86.08 and a 52-week high of $124.87. The company has a market cap of $153.10 billion, a price-to-earnings ratio of 24.58, a PEG ratio of 0.81 and a beta of 0.32. The company has a quick ratio of 1.15, a current ratio of 1.32 and a debt-to-equity ratio of 1.13.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 EPS for the quarter, topping analysts’ consensus estimates of $2.16 by $0.31. The business had revenue of $7.77 billion during the quarter, compared to analysts’ expectations of $7.42 billion. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The company’s quarterly revenue was up 3.0% on a year-over-year basis. During the same quarter in the previous year, the company earned $2.02 earnings per share. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. Equities analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 30th. Investors of record on Monday, December 15th will be given a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a dividend yield of 2.6%. The ex-dividend date is Monday, December 15th. Gilead Sciences’s payout ratio is presently 48.99%.

Insider Activity at Gilead Sciences

In other news, insider Johanna Mercier sold 28,000 shares of the stock in a transaction dated Friday, August 15th. The shares were sold at an average price of $118.53, for a total value of $3,318,840.00. Following the completion of the sale, the insider directly owned 114,168 shares in the company, valued at $13,532,333.04. This represents a 19.70% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Andrew D. Dickinson sold 2,500 shares of the firm’s stock in a transaction dated Wednesday, October 15th. The stock was sold at an average price of $118.08, for a total transaction of $295,200.00. Following the completion of the transaction, the chief financial officer directly owned 157,055 shares in the company, valued at approximately $18,545,054.40. This represents a 1.57% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 71,500 shares of company stock valued at $8,336,040. 0.27% of the stock is owned by insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.